"Digestive Disorders Associates specializes in the diagnosis and treatment of adults and children with GI diseases and disorders. Our team of gastroenterologists has expertise in all types of digestive conditions, including acid reflux disease, Crohn’s and ulcerative colitis, IBS, swallowing disorders and hepatitis. Patients of DDA can choose to be seen in Annapolis, Chester, or Gambrills, Maryland. As a smaller practice with three locations, our doctors are able to offer a more personalized, caring approach to their patients. During your initial consultation, your physician will listen patiently to your concerns. He or she will carefully review your GI symptoms and medical history."

During the past decade, Digestive Disorders Associates conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 3 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Digestive Disorders Associates" #1 sponsor was "Abbott" with 3 trials, followed by "Bausch Health Americas, Inc." with 2 trials sponsored, "Otsuka Pharmaceutical Development & Commercialization, Inc." with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Colotech A/S" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

According to Clinical.Site data, the most researched conditions in "Digestive Disorders Associates" are "Crohn's Disease" (5 trials), "Ulcerative Colitis" (5 trials), "Adenomatous Polyps" (1 trials), "Inflammatory Bowel Disease" (1 trials) and "Irritable Bowel Syndrome" (1 trials). Many other conditions were trialed in "Digestive Disorders Associates" in a lesser frequency.

Most popular intervention types in "Digestive Disorders Associates" are "Drug" (9 trials), "Biological" (3 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "0.5 mg calcitriol (1a -25-dihydroxycholecalciferol)" (1 trials), "75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3)" (1 trials), "Adalimumab (D2E7)" (1 trials), "Adalimumab 40 mg eow or ew" (1 trials) and "Asacol 400 mg (mesalamine)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Digestive Disorders Associates" are 12 trials for "All" genders.

Currently, there are NaN active trials in "Digestive Disorders Associates". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Digestive Disorders Associates, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Digestive Disorders Associates, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".